Ilya Pharma

11:00 AM - 11:15 AM, Wednesday, October 23, 2019 ・ 2nd Floor
Ilya Pharma develops next-generation biologics for treatment of wounds and skin and mucosa

The first indication targeted is treatment of difficult to heal skin wounds in specific populations for accelerated healing, reduced infection rates and minimal scarring. The lead drug candidate, ILP100, being tested in a first in human study, has potential to change the field of wound care and be a significant part in development of next-generation biologics. The second indication targeted is inflammatory bowel disease, this project is currently in research stage. More specifically human therapeutic well-known proteins are delivered on site by living lactic acid bacteria acting like small bioreactors. The company has own drug candidates and a highly skilled international team.
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Sweden
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
ILP100 topical
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2